A Phase 2 Study of LY2835219 for Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

Trial Profile

A Phase 2 Study of LY2835219 for Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs Abemaciclib (Primary)
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms MONARCH 1
  • Sponsors Eli Lilly
  • Most Recent Events

    • 12 Oct 2017 Results assessing the relationships between patient-reported symptoms and survival among patients with hr+/her2- metastatic breast cancer (mbc) treated with abemaciclib, were presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 28 Sep 2017 Based on the data from this trial, the US FDA has abemaciclib as monotherapy for women and men with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting, as reported in a Food and Drug Administration media release.
    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top